文献リスト

1) Turner-Warwick M, Lebowitz M, Burrows B, et al. Cryptogenic fibrosing alveolitis and lung cancer. Thorax. 1980; 35: 496-9

2) Park J, Kim DS, Shim TS, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2001; 17: 1216-9

3) Ozawa Y, Suda T, Naito T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009; 14: 723-8

4) American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002; 165: 277-304

5) Le Jeune I, Gribbin J, West J, et al. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med. 2007; 101: 2534-40

6) Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. Population-based cohort study. Am J Respir Crit Care Med. 2000; 161: 5-8

7) Kawai T, Yakumaru K, Suzuki M, et al. Diffuse interstitial pulmonary fibrosis and lung cancer. Acta Pathol Jpn. 1987; 37: 11-9

8) 松下 央. 特発性間質性肺炎と肺癌. 病理と臨床. 1993; 11: 178-82

9) Kawasaki H, Nagai K, Yoshida J, et al. Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol. 2002; 81: 33-7

10) 福島一雄, 河端美則, 内山隆司, 他. 限局性慢性間質性肺炎(限局性UIP)127例の予後―びまん性間質性肺炎への進展の可能性. 日本呼吸器学会雑誌. 1999; 37: 177-82

11) 千田雅之, 半田政志, 小野修一, 他. 肺癌切除例における限局性間質性肺炎所見の発現と術後間質性肺炎に関する検討. 肺癌. 2001; 41: 105-9

12) Takahashi T, Munakata M, Ohtsuka Y, et al. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis. Cancer. 2002; 95: 624-33

13) Kuwano K, Kunitake R, Kawasaki M, et al. P21 Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1996; 154: 477-83

14) Hojo S, Fujita J, Yamadori I, et al. Heterogeneous point mutations of the p53 gene in pulmonary fibrosis. Eur Respir J. 1998; 12: 1404-8

15) Uematsu K, Yoshimura A, Gemma A, et al. Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res. 2001; 61: 8527-33

16) Kondoh Y, Taniguchi H, Kawabata Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis: analysis of clinical and pathological findings in three cases. Chest. 1993; 103: 1808-12

17) Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J. 2003; 22: 821-6

18) Koizumi K, Hirata T, Hirai K, et al. Surgical treatment of lung cancer combined with interstitial pneumonia: the effect of surgical approach on postoperative acute exacerbation. Ann Thorac Cardiovasc Surg. 2004; 10: 340-46

19) Chiyo M, Sekine Y, Iwata T, et al. Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg. 2003; 126: 1141-6

20) Watanabe A, Higami T, Ohori S, et al. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis？ J Thoracic Surg. 2008; 136: 1357-63

21) Chida M, Ono S, Hoshikawa Y, et al. Subclinical idiopathic pulmonary fibrosis is also a risk factor of postoperative acute respiratory distress syndrome following thoracic surgery. Eur J Cardiovasc Surg. 2008; 34: 878-81

22) Minegishi Y, Takenaka K, Mizutani H, et al. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med. 2009; 48: 665-72

23) 竹中 圭, 吉村明修, 岡野哲也, 他. 特発性間質性肺炎(IIP)合併肺癌における肺癌治療に伴うIIP急性増悪の検討. 肺癌. 1999; 39: 955-62

24) 埴淵昌毅, 山口俊彦, 岡田達也, 他. 特発性間質性肺炎(IIP)合併肺癌に対する肺癌治療後IIP急性増悪症例の臨床的検討. 肺癌. 2001; 41: 281-6

25) 磯部和順, 秦 美暢, 杉野圭史, 他. 間質性肺炎合併肺癌における治療後急性増悪の検討. 肺癌. 2007; 47: 849-54

26) 佐藤和広, 島岡雄一, 林 芳樹, 他. 間質性肺炎合併肺癌の化学療法後の急性増悪例の臨床的検討. 癌と化学療法. 2009; 36: 1493-7

27) 竹内栄治, 山口俊彦, 森 雅秀, 他. 肺癌を合併した特発性間質性肺炎症例の臨床的検討. 日本胸部疾患学会雑誌. 1996; 34: 653-8

28) 弦間昭彦, 峯岸裕司. 特発性間質性肺炎合併肺癌に対する化学療法の現況と治療関連急性増悪に関する実態調査. びまん性肺疾患に関する調査研究班. 平成21年度研究報告書. 2010; 105-7

29) Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171: 1040-7

30) Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 35: 821-9

31) Kim DS, Park JH, Park BK. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006; 27: 143-50

32) Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest. 2007; 132: 214-20

33) Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 2008; 177: 1348-57

34) Minegishi Y, Sudoh J, Kuribayasi H, et al. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 2010 May 19 [Epub]

35) 峯岸裕司, 須藤淳子, 河野あゆみ, 他. 特発性間質性肺炎合併進行小細胞肺癌に対するカルボプラチン＋エトポシド療法のパイロット研究. (会議録)日本内科学会雑誌. 2010; 99 Suppl: 236

36) 工藤翔二, 川俣仲秋, 家城隆次, 他. 特発性間質性肺炎合併肺癌の治療に関するレトロスペクティブな検討. 厚生省特定疾患びまん性肺疾患調査研究班. 平成3年度研究報告書. 1992. p.78-80

37) 山岡憲夫, 内山貴尭, 田川 努, 他. 特発性間質性肺炎を合併した肺癌切除例の検討 特に周術期, 退院後の管理について. 日本呼吸器外科学会雑誌. 1999; 13: 15-20

38) 青山克彦, 金沢 実, 金子公一, 他. 肺線維化病変合併肺癌症例の術後急性増悪に対するステロイド予防投与. 臨床呼吸生理. 2003; 35: 123-6

39) 村岡昌司, 赤嶺晋治, 土谷智史, 他. 間質性肺炎合併肺癌の周術期ステロイドおよびerythromycin投与の有用性. 胸部外科. 2007; 60: 871-5

40) Graham MV, Graham MV, Purdy JA, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999; 45: 323-9

41) Tsujino K, Hirota S, Endo M, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 2003; 55: 110-5

42) Byhardt RW, Scott C, Sause WT, et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1998; 42: 469-78

43) Inoue A, Kunitoh H, Sekine I, et al. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys. 2001; 49: 649-55

44) Makimoto T, Tsuchiya S, Hayakawa K, et al. Risk factors for severe radiation pneumonitis in lung cancer. Jpn J Clin Oncol. 1999; 29: 192-7

45) Ohe Y, Yamamoto S, Suzuki K, et al. Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer. 2001; 37: 54-63

46) 高尾仁二, 島本 亮, 新保秀人, 他. 間質性肺炎合併肺癌の術後再発に対する経皮的ラジオ波焼灼術を用いた局所療法. 胸部外科. 2005; 58: 53-7

47) 千田雅之, 高橋博人, 山中秀樹, 他. 限局性間質性肺炎からの肺癌手術後急性増悪例の検討. 胸部外科. 2005; 58: 22-5

48) Chida M, Ono S, Hoshikawa Y, et al. Subclinical idiopathic pulmonary fibrosis is also a risk factor of postoperative acute respiratory distress syndrome following thoracic surgery. Eur J Cardiothorac Surg. 2008; 34: 878-81

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp